source
- MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy. The study evaluated a once‑daily dosing regimen and failed to meet the predefined p…
- Sarepta Therapeutics appoints Michael Severino, former Tessera CEO, as new chief executiveSarepta Therapeutics announced that Michael Severino will become its chief executive, effective Tuesday. Severino previously led Tessera Therapeutics. He replaces Doug Ingram, who said he will ret…